Found 2 results
Filters: Author is H. Yüce  [Clear All Filters]
O. A. Uyar, Kara, M., Erol, D., Ardicoglu, A., and Yüce, H., Investigating paraoxonase-1 gene Q192R and L55M polymorphism in patients with renal cell cancer, vol. 10, pp. 133-139, 2011.
Akcay MN, Polat MF, Yilmaz I and Akcay G (2003a). Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 50 (Suppl 2): CCXXV-CCXXVII. PMid:15244186   Akcay MN, Yilmaz I, Polat MF and Akcay G (2003b). Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50 (Suppl 2): CCLXXIII-CCLXXV. PMid:15244199   Antognelli C, Mearini L, Talesa VN, Giannantoni A, et al. (2005). Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63: 240-251. PMid:15538743   Azarsiz E and Sonmez EY (2000). Paraoxonase and clinical importance. Turk. J. Biochem. 25: 109-119.   Bonnefont-Rousselot D, Therond P, Beaudeux JL, Peynet J, et al. (1999). High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin. Chem. Lab. Med. 37: 939-948. PMid:10616747   Campbell SC (1997). Advances in angiogenesis research: relevance to urological oncology. J. Urol. 158: 1663-1674.   Chow WH, Devesa SS, Warren JL and Fraumeni JF Jr (1999). Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631. PMid:10235157   Clifford SC, Prowse AH, Affara NA, Buys CH, et al. (1998). Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22: 200-209.<200::AID-GCC5>3.0.CO;2-#   Connolly JL, Schnitt SJ, Wang HH, Longtine JA, et al. (2003). Principles of Cancer Pathology. In: Cancer Medicine (Kufe DW, Pollock RE and Weichselbaum RR, eds.). Hamilton-BC Decker, London, 487-502.   Durrington PN, Mackness B and Mackness MI (2001). Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 473-480. PMid:11304460   Elkiran ET, Mar N, Aygen B, Gursu F, et al. (2007). Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 7: 48. PMid:17362500 PMCid:1839096   Gago-Dominguez M and Castelao JE (2006). Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic. Biol. Med. 40: 721-733. PMid:16458203   Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, et al. (2002). Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 13: 287-293. PMid:12020111   Hassett C, Richter RJ, Humbert R, Chapline C, et al. (1991). Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30: 10141-10149. PMid:1657140   Landis SH, Murray T, Bolden S and Wingo PA (1999). Cancer statistics. CA Cancer J. Clin. 49: 8-31. PMid:10200775   Lusini L, Tripodi SA, Rossi R, Giannerini F, et al. (2001). Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int. J. Cancer 91: 55-59.<55::AID-IJC1006>3.0.CO;2-4   Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1997). Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122: 265-268. PMid:9313934 PMCid:1564940   Mackness MI, Arrol S and Durrington PN (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.   Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76. PMid:8743898   Playfer JR, Eze LC, Bullen MF and Evans DA (1976). Genetic polymorphism and interethnic variability of plasma paroxonase activity. J. Med. Genet. 13: 337-342. PMid:1003443 PMCid:1013436   Pljesa-Ercegovac M, Mimic-Oka J, Dragicevic D, Savic-Radojevic A, et al. (2008). Altered antioxidant capacity in human renal cell carcinoma: role of glutathione associated enzymes. Urol. Oncol. 26: 175-181. PMid:18312938   Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507. PMid:8661009   Storkel S, Eble JN, Adlakha K, Amin M, et al. (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987-989. PMid:9307203   Van Der Logt EM, Janssen CH, Van Hooijdonk Z, Roelofs HM, et al. (2005). No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res. 25: 1465-1470. PMid:15865106   Whang M, O'Toole K, Bixon R, Brunetti J, et al. (1995). The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J. Urol. 154: 968-970.
Z. S. Özkan, Deveci, D., E. Önalan, E., and Yüce, H., Lack of effect of bone morphogenetic protein 2 and 4 gene polymorphisms on bone density in postmenopausal Turkish women, vol. 9, pp. 2311-2316, 2010.
Baylink DJ, Strong DD and Mohan S (1999). The diagnosis and treatment of osteoporosis: future prospects. Mol. Med. Today 5: 133-140.   Brochmann EJ, Behnam K and Murray SS (2009). Bone morphogenetic protein-2 activity is regulated by secreted phosphoprotein-24 kd, an extracellular pseudoreceptor, the gene for which maps to a region of the human genome important for bone quality. Metabolism 58: 644-650. PMid:19375587   Choi JY, Shin CS, Hong YC and Kang D (2006). Single-nucleotide polymorphisms and haplotypes of bone morphogenetic protein genes and peripheral bone mineral density in young Korean men and women. Calcif. Tissue Int. 78: 203-211. PMid:16604289   Ferrari S (2008). Human genetics of osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab. 22: 723-735. PMid:19028354   Flicker L, Hopper JL, Rodgers L, Kaymakci B, et al. (1995). Bone density determinants in elderly women: a twin study. J. Bone Miner. Res. 10: 1607-1613. PMid:8592936   Ichikawa S, Johnson ML, Koller DL, Lai D, et al. (2006). Polymorphisms in the bone morphogenetic protein 2 (BMP2) gene do not affect bone mineral density in white men or women. Osteoporos. Int. 17: 587-592. PMid:16432645   Ireland P, Jolley D, Giles G, O'Dea K, et al. (1994). Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac. J. Clin. Nutr. 3: 19-31.   Mangino M, Torrente I, De Luca A, Sanchez O, et al. (1999). A single-nucleotide polymorphism in the human bone morphogenetic protein-4 (BMP 4) gene. J. Hum. Genet. 44: 76-77. PMid:9929985   Medici M, van Meurs JB, Rivadeneira F, Zhao H, et al. (2006). BMP-2 gene polymorphisms and osteoporosis: the Rotterdam Study. J. Bone Miner. Res. 21: 845-854. PMid:16753015   Ramesh Babu L, Wilson SG, Dick IM, Islam FM, et al. (2005). Bone mass effects of a BMP4 gene polymorphism in postmenopausal women. Bone 36: 555-561. PMid:15777683   Richards JB, Rivadeneira F, Inouye M, Pastinen TM, et al. (2008). Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371: 1505-1512.   Richards JB, Kavvoura FK, Rivadeneira F, Styrkarsdottir U, et al. (2009). Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann. Intern. Med. 151: 528-537. PMid:19841454 PMCid:2842981   Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, et al. (2009). Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 41: 1199-1206. PMid:19801982 PMCid:2783489   Sengle G, Charbonneau NL, Ono RN, Sasaki T, et al. (2008). Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J. Biol. Chem. 283: 13874-13888. PMid:18339631 PMCid:2376219   Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, et al. (2003). Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol. 1: E69. PMid:14691541 PMCid:270020   Takahashi T, Morris EA and Trippel SB (2007). Bone morphogenetic protein-2 and -9 regulate the interaction of insulin-like growth factor-I with growth plate chondrocytes. Int. J. Mol. Med. 20: 53-57. PMid:17549388   Wang EA, Rosen V, D'Alessandro JS, Bauduy M, et al. (1990). Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. U. S. A. 87: 2220-2224. PMid:2315314 PMCid:53658   Young D, Hopper JL, Nowson CA, Green RM, et al. (1995). Determinants of bone mass in 10- to 26-year-old females: a twin study. J. Bone Miner. Res. 10: 558-567. PMid:7610926   Zhou H, Qian J, Wang J, Yao W, et al. (2009). Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N, 6-O-sulfated chitosan in vitro and in vivo. Biomaterials 30: 1715-1724. PMid:19131102